ASH 2023 | Long-term outcomes from key clinical trials presented at ASH 2023
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, summarizes some of the highlights from the abstracts presented at the 2023 ASH meeting. Several abstracts included long-term follow-up data from pivotal clinical trials, which are essential to determine whether novel therapies continue to effectively manage disease in the long term. Dr Kamdar briefly discusses some key trials and therapies covered at the meeting, including the ELEVATE-TN trial (NCT02475681) of acalabrutinib in chronic lymphocytic leukemia (CLL), doublet combinations such as mosunetuzumab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), and the use of measurable residual disease (MRD)-driven strategies such as that used in the BOVen trial (NCT03824483). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, syncopation, caribou biosciences
DMC: Genentech, Celgene
Research Funding: Novartis
Speakers Bureau: SeaGen
